Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for Chemotherapy-Induced Nausea and Vomiting in Metastatic Pancreatic Cancer
NCT06017284Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Nov 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of thalidomide in chemotherapy-induced nausea and vomiting (CINV), sponsored by Fudan University. Started Nov 2023; status: recruiting.
02
Drugs
thalidomide
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT06017284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06017284.